NEW YORK (GenomeWeb News) — Orchid Cellmark said yesterday it plans to buy Reliagene Technologies, a forensic and paternity DNA-analysis company, for $5.6 million in cash and $3 million in Orchid Cellmark restricted common stock.
 
Reliagene, which earned $7.5 million in revenue in 2006, “fits the criteria we are seeking in accelerating the growth of our business through acquisitions,” Orchid CEO Thomas Bologna said in a statement.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers in China have generated mouse pups from same-sex parents, according to Scientific American.

Two research teams find a role for PIEZO2 in touch sensitivity after injury and inflammation.

The South China Morning Post reports that Hong Kong plans to add HK$20 billion (US$2.6 billion) to a research endowment.

In Science this week: open genetic genealogy databases can lead to the identification of individuals who have not sought testing, and more.